ClinicalTrials.gg
RecruitingNCT07130526Updated Aug 19, 2025

Distrupt Stiffness Trial

An interventional study of Intravascular Lithotripsy (IVL) plus DCB and POBA plus DCB in PAD - Peripheral Arterial Disease and PAD, sponsored by University Hospital, Essen. Recruiting at 2 sites in Germany. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-08-19.

Primary conditionPeripheral Arterial DiseaseRegistry: Peripheral Vascular DiseasesReclassifiedWhy we changed it
Registry
Peripheral Vascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Peripheral Arterial Disease
Why
  1. The study's listed conditions name Peripheral Arterial Disease, a narrower term within Peripheral Vascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Hospital, Essen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 173 studies in Peripheral Arterial Disease with a site in Germany — 15 open to participants now, 29 under way, 3 of them phase 3. Peripheral Arterial Disease · Germany.

Planned enrollment
103rd of 126
40 · median 107
Started
2025
with 2 others
No phase
85 of 173
8 open now
Primary completion
2026-04
later than 13 of 28 live
Registered
172nd of 173
by date
Lead sponsor
8 of 173
University Hospital, Essen

Among the 173 studies in Peripheral Arterial Disease with a site in Germany, this one is the 103rd largest by planned enrollment of the 126 interventional ones that give a count, is one of 3 that started in 2025, is one of 85 with no phase, reaches primary completion later than 13 of the 28 other live ones, and was the 172nd registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

15 of the 173 studies in Peripheral Arterial Disease with a site in Germany are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Peripheral Arterial Disease with a site in Germany, or all of them as a file.
02

Study summary

Typical symptoms of PAD include exercise-induced pain in the legs (known as intermittent claudication), which can significantly limit pain-free walking. In more advanced stages, pain may also occur at rest. Additionally, the development of chronic, hard-to-heal wounds-especially on the feet and toes-is possible. These wound healing impairments are caused by the insufficient supply of oxygen and nutrients to the affected tissues.

The underlying cause of PAD is usually atherosclerosis, a pathological change in the vessel walls due to the accumulation of fats, calcium, and connective tissue. These deposits lead to stiffening and narrowing of the arteries, severely restricting blood flow. Major risk factors for the development of PAD include widespread chronic conditions such as diabetes mellitus, hyperlipidemia (elevated blood lipid levels, e.g., cholesterol), arterial hypertension (high blood pressure), obesity, and tobacco use.

Various therapeutic options are available for the treatment of PAD. In addition to conservative therapy (such as supervised exercise training, pharmacological blood thinning, and risk factor management), interventional, minimally invasive treatment using catheter-based techniques is frequently employed. In such procedures, a thin catheter is guided through the vascular system to the affected area of the leg artery. Depending on the type and extent of the arterial narrowing or calcification, one of the following techniques may be applied:

Balloon angioplasty: Dilation of the vessel using an inflatable balloon. Lithoplasty: Application of shockwaves to break down calcifications in the arterial wall.

Read the detailed description

Massive Calcifications in the peripheral vessels lead to altered vascular stiffness. This arterial stiffness is an excellent marker for morbidity and mortality and correlates with the progression of cardiovascular disease. Main pathophysiologic principles are altered pulse wave reflections through arterial and aortic stiffness on cardiac functions. Impaired vascular compliance is associated with increased cardiovascular morbidity and leads to a progression of atherosclerotic lesions, impaired ventriculoarterial coupling and ultimately impaired coronary perfusion.

Vascular calcifications are furthermore held responsible for suboptimal vessel expansion and increased risk of complications including dissection and perforation and reduced long-term patency when treated though the endovascular route. Calcium treatment through IVL gives physicians opportunities to tackle this unmet need. IVL treatment is a safe and effective treatment in these heavily calcified lesions proving excellent procedural success compared to PTA driven by a significantly lower rate of major dissections and need for bail-out stent placement. This was evident also in coronary vessels suggesting that calcium fracture is the IVL-related mechanism to enhance vessel compliance and to assists optimal stent expansion.

The influence of this novel strategies with improved hemodynamic capabilities with respect to vasomotion of the vessel wall, vascular function and vascular compliance can be measured by ultrasound, as shown recently. To which extent intravascular lithotripsy has an impact on vessel compliance has not been elucidated so far and could aid to understand the prognostic beneficial effects of intravascular lithotripsy.

The aim of this investigator-initiated trial is thus to investigate the IVL -related beneficial effect of lesion preparation by altering vascular compliance parameters and vasomotion of the vessel wall.

The primary objective is to determine changes in Vessel compliance, function and stiffness and after IVL treatment compared to POBA in symptomatic PAD.

Local vascular compliance as determined through FDC (fractional diameter change) in the distal IEA, CFA, prox. SFA or PA. Measurement of vascular compliance or function in patients is a powerful tool for atherosclerosis research. FDC represents the ratio of the vessel's diameter change between systole and diastole divided by the diastolic diameter. Several interventions are known to decrease cardiovascular risk, including exercise, smoking cessation, or medications with statins improving vascular compliance. Therefore, vascular compliance serves as a ''barometer'' for cardiovascular health that can be used for evaluation of new therapeutic strategies and is prognostic relevant. Moreover numerous studies have proven the prognostic value of vasomotor dysfunction, demonstrating that impaired vasomotor function identifies patients who have increased risk for cardiovascular events. Until now, it is completely unknown if intravascular lithotripsy has an impact on local vascular functions. We have recently shown an impact of paclitaxel coated ballons and mechanical atherothrombectomy on local vascular functions.

Further outcome measures include local and systemic vascular function and stiffness determined through pulse wave velocity (PWV), flow-mediated dilatation (FMD) and augmentation index (augmentation index). Vascular and aortic stiffness, assessed by measurement of PWV, can predict future cardiovascular events and mortality, even after accounting for other established cardiovascular risk factors. During the last years, a large amount of evidence has accumulated demonstrating that arterial stiffness is an important risk factor for cardiovascular disease. FMD represents the percent diameter gain as calculated based on pre-ischemia and post-ischemia (and reactive hyperemia) diameter measurements of the femoral artery. In this context, ischemia is induced through vessel occlusion by means of inflating a blood pressure cuff around the forearm or leg. Standard techniques as determined by Doppler and duplex ultrasonography will quantify tissue perfusion and primary patency. Furthermore, technical success, procedural complications and freedom from target lesion revascularization will be determined.

Peripheral Lithotripsy System The device under investigation is the Peripheral Lithotripsy System (Shockwave Medical, Fremont, California). Miniaturized and arrayed lithotripsy emitters create a localized field effect at the site of the calcium. The Peripheral Lithotripsy System is CE-marked for peripheral arterial disease and for this study, will be used within its indication for use. This included the following: intended for lithotripsy-enhanced balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral and popliteal arteries.

The IVL catheter is delivered across a calcified lesion over an 0.014'' wire and the integrated balloon is expanded to 4atm to facilitate efficient energy transfer.

An electrical discharge from the emitters vaporizes the fluid within the balloon, creating a rapidly expanding and collapsing bubble that generates sonic pressure waves. The waves create a localized field effect that travels through soft vascular tissue, selectively cracking intimal and medial calcium within the vessel wall.

After calcium modification, the integrated balloon may subsequently be used to dilate the lesion at low pressure to maximize luminal gain.

03

Conditions studied

  • PAD - Peripheral Arterial Disease
  • PAD

Browse trials for

Keywords

  • pad
  • peripheral artery disease
  • intravascular lithotripsy
04

In context

Peripheral Arterial Disease Reclassified

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

This study's planned enrollment of 40 is below the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.

Browse Peripheral Arterial Disease studies →

Lead sponsor

University Hospital, Essen is the lead sponsor of 118 studies on the registry; 35 are open to participants now.

Compared within Peripheral Arterial Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Vascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Peripheral artery disease
  • Severe Calcification PACCS 2,3 and 4
  • Target lesions in distal EIA, CFA, prox. SFA or PA
  • Clinical diagnosis of chronic, symptomatic lower limb ischemia as defined by Rutherford 2, 3, 4 and 5
  • Planed peripheral intervention TASC A-D
  • Subject must be between 18 and 85 years old
  • Willing to comply with the specified follow-up evaluation
  • Written prior to any study procedures

Exclusion criteria

Exclusion Criteria:

  • Target lesions with no optimal visualization in ultrasound
  • Instent-Restenosis
  • Thrombolysis within 72 hours prior to the index procedure
  • Aneurysm formations in the femoral artery or popliteal artery
  • Concomitant hepatic insufficiency, deep venous thrombus, coagulation disorder or receiving therapy
  • Unstable angina pectoris at the time of the enrolment
  • Recent myocardial infarction or stroke \< 30 days prior to the index procedure
  • less than 12 months
  • Septicemia at the time of enrolment
  • Known or suspected active infection at the time of the index procedure, excluding an infection of a lower extremity wound of the target limb
  • Known or suspected allergies or to aspirin, clopidogrel or heparin
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    POBA plus DCB

    Device: POBA plus DCB

  • Active comparator
    Intravascular Lithotripsy (IVL) plus DCB

    Device: Intravascular Lithotripsy (IVL) plus DCB

Interventions

  • DeviceIntravascular Lithotripsy (IVL) plus DCB

    The device under investigation is the Peripheral Lithotripsy System (Shockwave Medical, Fremont, California). Miniaturized and arrayed lithotripsy emitters create a localized field effect at the site of the calcium. The Peripheral Lithotripsy System is CE-marked for peripheral arterial disease and for this study, will be used within its indication for use. This included the following: intended for lithotripsy-enhanced balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral and popliteal arteries. The IVL catheter is delivered across a calcified lesion over an 0.014'' wire and the integrated balloon is expanded to 4atm to facilitate efficient energy transfer. An electrical discharge from the emitters vaporizes the fluid within the balloon, creating a rapidly expanding and collapsing bubble that generates sonic pressure waves. The waves create a localized field effect that travels through soft vascular tissue,

  • DevicePOBA plus DCB

    Standard of Care

07

What researchers measure

Primary outcomes

  1. FDC

    To determine changes in vessel compliance before and after IVL treatment and after 1 month compared to POBA in symptomatic PAD as determined by fractional diameter change (FDC).

    Time frame: 1 day and 30 days follow-up

Secondary outcomes

  1. FMD/NMD analysis of the target lesion

    • Endothelial function and endothelial independent function as determined by FMD/NMD analysis of the target lesion. FMD represents the percent diameter gain as calculated based on preischemia and postischemia diameter measurements of the femoral artery. NMD represents the diameter change of the femoral artery after nitroglycerine-mediated vasodilation.

    Time frame: 1 day and 30 days follow-up

  2. PWV

    Aortic stiffness determined by pulse wave velocity (PWV)

    Time frame: 1 day and 30 days follow-up

  3. ABI

    Peripheral perfusion determined by ABI (ankle brachial index)

    Time frame: 1 day and 30 days follow-up

  4. Primary patency (PP)

    Primary patency (PP) evaluated by clinical assessment by ultrasound

    Time frame: 1 day and 30 days follow-up

  5. AIX

    Arterial stiffness determined by augmentation index (AIX@75HR). Changes in cardiovascular function measured by augmentation index in percent

    Time frame: 1 day and 30 days follow-up

  6. Procedural complications

    Procedural complications

    Time frame: 1 day and 30 days follow-up

  7. Dissection rate and Bail-out stenting

    Dissection rate and Bail-out stenting in % of treated patients

    Time frame: 1 day and 30 days follow-up

  8. Freedom from Target Lesion Revascularization (FTLR)

    Freedom from Target Lesion Revascularization (FTLR)

    Time frame: 1 day and 30 days follow-up

08

Study locations

1 of 2 sites recruiting
  • West German Heart and Vascular Center, Clinic for Cardiology and Vascular Medicine, Universtiy Hospital Essen
    Essen, North Rhine-Westphalia 45147, Germany
    Not yet recruiting
  • University of Duisburg-Essen
    Essen, 45147, Germany
    Recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Apr 2026, 9 months after the start.

Of 261 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 9 months is below that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2025
First posted
Aug 19, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Apr 20, 2026
CompletionEst.
Jun 20, 2026
Last update
Aug 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07130526
Responsible party
Sponsor
First posted
Aug 19, 2025
Start date
Jul 1, 2025
Primary completion
Apr 20, 2026 (estimated)
Completion
Jun 20, 2026 (estimated)
Last update
Aug 19, 2025

Study contacts

Christos Rammos, Prof. Dr. med.
Contact
christos.rammos@uk-essen.de
0201-723-4801
Daniel Messiha, Dr. med.
Contact
daniel.messiha@uk-essen.de
0201-723-4801

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion